Clinical trial
A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.
NCT06789796 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- February 28, 2025
- Completion date
- March 31, 2030
- Enrollment
- 636 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
small-cell lung cancer